Wave Life Sciences Announces Major Public Offering
Wave Life Sciences Ltd. is embarking on an exciting journey by initiating a public offering involving $250 million worth of its ordinary shares. This move aims to strengthen the company’s commitment to pioneering RNA medicines that have the potential to reshape the landscape of human health.
Offering Details and Underwriters
The offering will also include the option for select investors to purchase pre-funded warrants as an alternative to ordinary shares. In an effort to make this offering more appealing, Wave Life Sciences has granted underwriters a 30-day option to purchase up to an additional 15% of the total offering amount. The selling of these securities is exclusively conducted by Wave Life Sciences, ensuring that all raised funds are directly channelled into their innovative programs.
Key Players in the Offering
Jefferies, Leerink Partners, and BofA Securities are the notable joint book-running managers for this offering, signaling a strong examination of market conditions that will dictate the success of this venture. While the ultimate completion of the offering depends on these external conditions, the anticipation around the company's ability to attract keen investors remains high.
Prospectus and Regulations
All offerings are facilitated by an effective shelf registration statement previously filed with the SEC. The details surrounding the offering will be clearly outlined in a preliminary prospectus supplement that will be made available on the SEC's website. This will ensure transparency and accessibility for interested investors.
About Wave Life Sciences
Wave Life Sciences is dedicated to harnessing the vast potential of RNA medicines, contributing significantly to advancements in biotechnology. With their innovative PRISM® platform, the company is at the forefront of drug development, utilizing an array of RNA-targeting modalities such as editing, splicing, and silencing. This robust capability allows Wave to design tailored therapies that effectively address diverse disease biology.
Pioneering RNA Technologies
Wave’s diversified pipeline showcases significant clinical endeavors targeting various conditions including obesity, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington’s disease, along with an array of preclinical programs. The focus on transformative therapies highlights Wave's mantra to ‘Reimagine Possible,’ leading the advancement toward optimal human health.
Company Contact Information
If investors or media representatives would like more information, they can reach out directly to the company. Kate Rausch serves as the Vice President of Corporate Affairs and Investor Relations and can be contacted at +1 617-949-4827. For investor inquiries, James Salierno is the Director, who can provide insights at +1 617-949-4043.
Frequently Asked Questions
What is the purpose of Wave Life Sciences' public offering?
The public offering aims to secure funding to advance the company's RNA medicines research and clinical programs, helping to transform healthcare solutions.
Who are the joint managers for the public offering?
Jefferies, Leerink Partners, and BofA Securities are acting as the joint book-running managers for this $250 million offering.
Where can I find more information about the offering?
Details can be accessed through the SEC's website, where the preliminary prospectus supplement will be available.
What kind of therapies is Wave Life Sciences developing?
Wave Life Sciences is focused on developing RNA-targeting therapies for various conditions, including obesity, Duchenne muscular dystrophy, and Huntington’s disease among others.
How can I contact Wave Life Sciences for more information?
You can contact the Vice President, Kate Rausch, at +1 617-949-4827 or reach the Investor Relations team via James Salierno at +1 617-949-4043 for further inquiries.
